



Biom'up confirms the success of its IPO. Over-allotment option partially exercised

Reinforcement of shareholders' equity of €60 million through the initial public offering of which:

- **around €42.5 million within the frame of the offer**
- **€17.3 million in bonds capitalization**

Implementation of a liquidity contract with CM-CIC Market Solutions

Saint-Priest, France, November 9, 2017 – Biom'Up, specialist of surgical hemostasis, announces today the partial exercise of the over-allotment option in connection with its initial public offering on Euronext Paris' regulated market.

On November 9, 2017, Bryan Garnier & Co, acting as Global Coordinator Joint Lead Manager and Bookrunner, partially exercised the over-allotment option in respect of 416,736 additional new shares, raising a total of €4,375,728 at the offering price of €10.50 per share.

Accordingly, after partial exercise of the over-allotment option, the total number of Biom'Up's ordinary shares offered for sale in connection with its IPO stands at 4,048,315, representing 36.1% of its capital, thereby increasing the final size of the offering to around €42.5 million. Settlement and delivery of the additional new shares issued through partial exercise of the over-allotment option will take place on November 13, 2017.

Moreover, concurrently with the IPO, Biom'Up reiterates that it has proceeded to bonds capitalization issuing 2,788,624 new shares. This operation resulted in a capital increase of approximately €17.3 million and therefore a corresponding reduction in the Company's debt.

Biom'Up also announces that it has entrusted to CM-CIC Market Solutions the implementation of a liquidity contract in accordance with the Charter of Ethics established by the AMAFI from November 9, 2017 for a six-month period renewable by tacit agreement. The sum of €200,000 euros has been allocated to the liquidity account for the purposes of this contract.

Following the IPO and the exercise of the over-allotment option and Biom'Up's share capital and voting rights break down as follows:

Shareholders	Following initial public offering but excluding partial exercise of the Overallotment Option of 416 736 additional new shares		Following initial public offering including partial exercise of the Overallotment Option of 416 736 additional new shares	
	Number of shares	% of capital and voting rights	Number of shares	% of capital and voting rights
Bpifrance Participations	1,967,006	18.2%	1,967,006	17.5%
Bpifrance Investissement (InnoBio)	1,148,542	10.6%	1,148,542	10.2%
Sub-total Bpifrance	3,115,548	28.8%	3,115,548	27.8%
Gimv	1,364,272	12.6%	1,364,272	12.2%
Lundbeckfond Ventures	1,043,687	9.7%	1,043,687	9.3%
Sham Innovation Santé	778,138	7.2%	778,138	6.9%
Fonds Viveris	570,354	5.3%	570,354	5.1%
Mérieux Participations	267,088	2.5%	267,088	2.4%
Financial investors	7,139,087	66.1%	7,139,087	63.6%
Other shareholders	416,183	3.9%	416,183	3.7%
Founding partners and Board members	387,014	3.6%	387,014	3.4%
Other warrant and stock option holders	-	0.0%	-	0.0%
Float	2,860,623	26.5%	3,277,359	29.2%
TOTAL	10,802,907	100.0%	11,219,643	100.0%

Stabilisation activity details

In its role as stabilization agent, Bryan Garnier & Co states that it has entered into stabilization transactions for a total of 128,000 Biom'Up shares (FR0013284080) offered for sale in connection with Biom'Up's initial public offering.

The stabilization transactions commenced on October 13, 2017.

The final transactions were completed on November 8, 2017.

The stabilization transactions between October 13, 2017 and November 8, 2017 took place within the following price ranges:

Date	Lowest price	Highest price
Oct 13, 2017	10.28	10.50
Oct 16, 2017	10.31	10.44
Oct 17, 2017	10.05	10.46
Oct 18, 2017	10.00	10.27
Oct 19, 2017	9.45	10.23
Oct 20, 2017	9.95	9.95

Oct 23, 2017	9.90	9.90
Date	Lowest price	Highest price
Oct 24, 2017	-	-
Oct 25, 2017	9.65	9.75
Oct 26, 2017	9.50	9.72
Oct 27, 2017	9.30	9.76
Nov 2, 2017	9.05	9.16
Nov 3, 2017	9.10	9.35
Nov 6, 2017	9.44	9.44
Nov 7, 2017	9.19	9.44
Nov 8, 2017	9.05	9.32

Other information

- Issuer's name: Biom'Up
- Issuer's LEI: 969500N7YVUQKF0R5Q54
- Investment service provider's name: Bryan Garnier & Co
- Investment service provider's LEI: 213800QFPP8QFI9PUP95
- Financial instrument classification: ESVUFN
- Company name: BUP
- ISIN Code: FR0013284080
- Ticker: BUP
- Compartment: Euronext Paris (compartment C)
- Sector: 4573 – Biotechnology

•••

Financial intermediaries



*Global Coordinator
Joint Lead Manager and Bookrunner*



RBC Capital Markets

Joint Lead Manager and Bookrunner

Advisor



Advisor

Availability of the prospectus

Copies of the prospectus concerning the Offering and the listing of Biom'Up shares on the Euronext regulated market in Paris, which was granted a visa by the AMF on September 25, 2017 under reference number 17- 508, may be obtained free of charge and upon request from Biom'Up (Parc Technologique de Lyon, 8, allée Irène Joliot Curie, 69800 Saint-Priest, France), as well as from the Company's website (www.biomup.com) and the AMF website (www.amf-france.org).

Risk factors

Biom'Up draws your attention to Chapter 4, "Risk factors", of the *Document de base*, and in particular to the risk factors indicated in section 4.1 on business and product risks, 4.6.1 "Historical loss risk and future loss risk" and 4.6.5, "Liquidity risk", as well as Chapter 2 of the *Note d'opération* concerning the risk factors associated with the Offering, and in particular the risk factor entitled "The future issue of financial instruments, in particular in the framework of potential additional financing, could create a risk of dilution."

Contacts

Biom'Up

Chief Financial Officer
Jean-Paul Alvès
investisseurs@biomup.com
+33 (0)4 86 57 36 10

NewCap

Investor Relations
Tristan Roquet Montégon
biomup@newcap.eu
+33 (0)1 44 71 00 16

NewCap

Media Relations
Nicolas Merigeau
biomup@newcap.eu
+33 (0)1 44 71 94 98

About Biom'Up

Founded in 2005 and based in the Lyon suburb of Saint-Priest (France), Biom'Up designs hemostatic products based on patented biopolymers that aim to simplify surgical procedures in numerous specialties (spine, cardiothoracic, general, orthopedic, plastic) and give patients a better quality of life. Its flagship product, HEMOBLAST™ Bellows, is a unique hemostatic solution, ready to use (no preparation time needed, no need to mix, no heat required), usable once or several times during the surgery. Developed by a world-renowned scientific team, HEMOBLAST™ Bellows has obtained positive results for all the primary and secondary endpoints of Phase III of its pivotal study involving 412 patients in the United States. HEMOBLAST™ Bellows obtained its CE Mark in December 2016, and its PMA (Pre-Market Approval) application was submitted to the FDA (Food & Drug Administration) in July 2017 with a view to obtaining marketing approval in the United States in mid-2018. Since its creation, Biom'Up has benefited from the support of prominent European investors such as Bpifrance, Innobio, GIMV, Lundbeckfond, Mérieux Participation, SHAM and ACG, as well as all the Company's managers, who have invested €2 million in equity.

Disclaimer

This document does not constitute an offer to sell or the solicitation of an offer to buy the securities of Biom'Up in the United States or in any other jurisdiction.

The securities referred to herein may not be offered or sold in the United States or to US persons unless such securities are registered under the US Securities Act of 1933, as amended ("**US Securities Act**"), or an exemption from the registration requirements of the US Securities Act is available. Biom'Up shares have not been and will not be registered under the US Securities Act and Biom'Up does not intend to undertake a public offering of its securities in the United States.

This announcement is an advertisement and does not constitute a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and the Council (the “**Prospectus Directive**”), as amended, to the extent such Directive has been transposed in the relevant Member State of the European Economic Area.

With respect to the Member States of the European Economic Area, other than France, which have implemented the Prospectus Directive (each a “**Relevant Member State**”), no action has been undertaken or will be undertaken to make an offer to the public of the securities requiring a publication of a prospectus in any Relevant Member State, other than France. As a result, the new or existing shares of the Issuer may not be offered and will not be offered in any Relevant Member State, except as permitted under Article 3 of the Prospectus Directive and/or regulations applicable in the Relevant Member State.

For the purposes of this provision, an “offer to the public” in relation to the new or existing shares of the Issuer in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the new or existing shares of the Issuer to be offered so as to enable an investor to decide to purchase the new or existing shares of the Issuer, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State.

In the United Kingdom, this document does not constitute an approved prospectus for the purpose of and as defined in section 85 of the Financial Services and Markets Act 2000 (as amended) (the “**FSMA**”), has not been prepared in accordance with the Prospectus Rules issued by the UK Financial Conduct Authority (the “**FCA**”) pursuant to section 73A of the FSMA and has not been approved by or filed with the FCA or any other authority which would be a competent authority for the purposes of the Prospectus Directive. The new and existing shares in the Issuer may not be offered or sold and will not be offered or sold to the public in the United Kingdom (within the meaning of sections 85 and 102B of the FSMA) save in the circumstances where it is to be lawful to do so without an approved prospectus (within the meaning of section 85 of the FSMA) being made available to the public before the offer is made.

This document is for distribution in the United Kingdom only to persons who (i) have professional experience in matters relating to investments falling within section 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the “**Financial Promotion Order**”), (ii) are persons falling within sections 49(2)(a) to (d) (“high net worth bodies corporate, unincorporated associations etc”) of the Financial Promotion Order, or (iii) are persons otherwise permitted by law to receive it (all such persons together being referred to as “**Relevant Persons**”). In the United Kingdom this document is directed only at Relevant Persons and must not be distributed to, acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available in the United Kingdom only to Relevant Persons and will be engaged in only with Relevant Persons.

The release, publication or distribution of this document in certain jurisdictions may be restricted by laws or regulations. Persons in such jurisdictions into which this press release is released, published or distributed must inform themselves about and comply with such laws or regulations.